Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EOLS vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EOLS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)

EOLS Overall Winner 6-Pillar Tally: EOLS 5 – 1 TLPH Matrix Metrics: EOLS 5 – 5 TLPH

As of Nov 16, 2026, Evolus, Inc. (EOLS) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EOLS carries a Unified Composite Score of 41.8/100 (SELL) at $6.69 (24.9x Forward P/E, -5.4% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Defensive Composite Rating Caution: Although EOLS compares more favorably head-to-head, both EOLS (41.8/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: EOLS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.7); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EOLS vs TLPH
EOLS NASDAQ Head-to-Head Winner
Evolus, Inc. Common Stock
Pharmaceutical Preparations
$6.69
-3.88% 1D
Market Cap $475.2M
TTM Revenue $325M
Forward P/E 24.9x
Beta / 30D Vol 1.31β · 60% Vol
Unified Composite Score
41.8 / 100 SELL
Tech 29.0 Fund 54.0 Flow 72.0 Mom 39.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $7.19 · SMA50: $7.57
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (EOLS 5 – 1 TLPH)

Columns: Metric · EOLS · TLPH
1. Valuation Multiples TLPH
Forward P/E 24.9x 1.0x
Trailing P/E 14.9x 1.0x
PEG Ratio N/M N/M
EV / Revenue 1.8x N/M
2. Growth & Scale EOLS
Revenue Growth (YoY) +13.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $325M $1,000
Market Cap $475.2M $53.7M
3. Profitability & Quality EOLS
Gross Margin 66.1% N/A
Operating Margin -5.4% -1474700.0%
Net Profit Margin -9.6% 0.0%
Return on Equity (ROE) -18729.6% -143.4%
4. Balance Sheet & Cash Flow EOLS
Cash Generation (TTM) -$8.8M -$15M EBITDA
Cash Flow Margin -2.7% N/A
Net Cash / Leverage $124M Net Debt $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EOLS
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 46.4% (4th %ile) 118.4% (100th %ile)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EOLS
OpEx & R&D Intensity 71.5% of Rev ($233M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EOLS (5) vs TLPH (5)
Institutional Metric EOLS TLPH Criterion Row Edge
Market Capitalization
Scale
$475.2M $53.7M Larger Scale EOLS
Trailing P/E Ratio
Valuation
14.9x 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
24.9x 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+13.0% +0.0% Higher Growth EOLS
Operating Margin (TTM)
Profitability
-5.4% -1474700.0% Higher Margin EOLS
Net Profit Margin
Profitability
-9.6% 0.0% Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
-18729.6% -143.4% Higher ROE TLPH
52-Week Range Position
Momentum
52% ($4–$9) 20% ($1–$2) Stronger Trend EOLS
Beta / 30D Volatility
Risk Regime
1.31β · 60% Vol 1.11β · 58% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
41.8 / 100 (SELL) 37.1 / 100 (SELL) Higher Composite EOLS
Trailing 12M Revenue (USD)
Operating Scale
$325M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
66.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.8M ($124M Net Debt) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EOLS +14.52 pp
EOLS: -5.77% · TLPH: -20.29%
3M Horizon EOLS +10.63 pp
EOLS: -18.22% · TLPH: -28.85%
6M Horizon TLPH +6.15 pp
EOLS: +1.83% · TLPH: +7.98%
1Y Horizon EOLS +8.78 pp
EOLS: -9.23% · TLPH: -18.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EOLS vs TLPH. Trailing 12-month operating profitability (EOLS -5.4% vs TLPH -1474700.0%) and valuation multiples (EOLS 24.9x vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

EOLS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$325M
Gross Margin66.1%
Op. Margin-5.4%
ROE / Fwd P/E-18729.6% · 24.9x
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EOLS CONSOLIDATION
100d in phase · OBV DISTRIBUTION
Current IV 46.4%
IV Percentile 4th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EOLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EOLS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $475.2M market capitalization and -5.4% operating margin.
OpEx & R&D Reinvestment 71.5% of Rev ($233M)
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EOLS vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Evolus, Inc. (EOLS) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EOLS carries a Unified Composite Score of 41.8/100 (SELL) at $6.69 (24.9x Forward P/E, -5.4% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Defensive Composite Rating Caution: Although EOLS compares more favorably head-to-head, both EOLS (41.8/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: EOLS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.7); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EOLS leads the Growth & Scale pillar: EOLS posts +13.0% YoY revenue growth and +0.0% YoY earnings growth on $325M TTM revenue (66.1% gross margin, -5.4% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, EOLS generates $325M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, EOLS deploys 71.5% of Rev ($233M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. EOLS trades at 24.9x Forward P/E, 14.9x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-2.7% FCF margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EOLS (-18729.6% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, EOLS carries 46.4% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.31β · 60% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.